BioIntelliSense, a continuous health monitoring and clinical intelligence company, completed the acquisition of AlertWatch, an FDA-cleared, clinically proven patient monitoring solution provider. Financial terms were not disclosed. “The addition of AlertWatch offers healthcare providers comprehensive continuous monitoring solutions, and an accelerated path from adoption to full scale utilization. The patented AlertWatch multi-parameter interface displays and analyzes data from inpatient vitals, the electronic medical record (EMR), laboratory systems and BioIntelliSense medical-grade wearables, to provide clinical intelligence across care settings and acuity levels,” James Mault, BioIntelliSense Founder and CEO.